novo nordisk patent semaglutide Ozempic's problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite The semaglutide story: highlighting the

627,628,629 PARPs-mediated ADP-ribosylation accounts for up to 90% of the cellular intracellular NAD + consumption, leading to reduced NAD + availability for sirtuins

Immunity and Seasonal Resilience Delhi winters, Mumbai monsoons, and Chennais coastal humidity each take a toll on immunity

In studies of Ras-driven carcinogenesis in RDEB-severe generalized keratinocytes, retention of the amino-terminal NC1, the first noncollagenous fragment of type VII collagen, is tumorigenic in mice.[151] This retained sequence may mediate tumor-stroma interactions that promote carcinogenesis

PlushCare has successfully scaled this by offering same-day appointments where doctors coordinate labs and prescriptions in one workflow

Epithelial antimicrobial defence of the skin and intestine